Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

Published: April 8, 2013
Category: Bibliography > Papers
Authors: Chang HY, Clark JM, Richards TM, Segal JB, Singh S, Weiner JP
Countries: United States
Language: null
Types: Population Health
Settings: Health Plan, PCP

JAMA Intern Med 173:534-539.

Department of Medicine, Johns Hopkins University Schools of Medicine and Public Health, Baltimore, MD, USA

IMPORTANCE: Acute pancreatitis has significant morbidity and mortality. Previous studies have raised the possibility that glucagonlike peptide 1 (GLP-1)-based therapies, including a GLP-1 mimetic (exenatide) and a dipeptidyl peptidase 4 inhibitor (sitagliptin phosphate), may increase the risk of acute pancreatitis.

OBJECTIVE: To test whether GLP-1-based therapies such as exenatide and sitagliptin are associated with an increased risk of acute pancreatitis. We used conditional logistic regression to analyze the data.

DESIGN: Population-based case-control study.

SETTING: A large administrative database in the United States from February 1, 2005, through December 31, 2008.

PARTICIPANTS: Adults with type 2 diabetes mellitus aged 18 to 64 years. We identified 1269 hospitalized cases with acute pancreatitis using a validated algorithm and 1269 control subjects matched for age category, sex, enrollment pattern, and diabetes complications.

MAIN OUTCOME MEASURE: Hospitalization for acute pancreatitis.

RESULTS: The mean age of included individuals was 52 years, and 57.45% were male. Cases were significantly more likely than controls to have hypertriglyceridemia (12.92% vs 8.35%), alcohol use (3.23% vs 0.24%), gallstones (9.06% vs 1.34), tobacco abuse (16.39% vs 5.52%), obesity (19.62% vs 9.77%), biliary and pancreatic cancer (2.84% vs 0%), cystic fibrosis (0.79% vs 0%), and any neoplasm (29.94% vs 18.05%). After adjusting for available confounders and metformin hydrochloride use, current use of GLP-1-based therapies within 30 days (adjusted odds ratio, 2.24 [95% CI, 1.36-3.68]) and recent use past 30 days and less than 2 years (2.01 [1.37-3.18]) were associated with significantly increased odds of acute pancreatitis relative to the odds in nonusers.

CONCLUSIONS AND RELEVANCE: In this administrative database study of US adults with type 2 diabetes mellitus, treatment with the GLP-1-based therapies sitagliptin and exenatide was associated with increased odds of hospitalization for acute pancreatitis.

Comment in: Glucagonlike Peptide 1-based drugs and pancreatitis: clarity at last, but what about pancreatic cancer?Gier B, Butler PC. JAMA Intern Med. 2013 Apr 8; 173(7):539-41.

PMID: 23440284

Morbidity Pattern,Mortality Prediction,Medical Conditions,High Risk,United States,Acute Disease,Adolescent,Adult,Case-Control Studies,Dipepetidyl-Peptidase IV Inhibitors/adverse effects,Gender,Logistic Models,Middle Aged,Pancreatitis/therapy,Peptides/adverse effects,Pyrazines/adverse effects,Risk Factors,Sitagliptin Phosphate,Triazoles/adverse effects,Venoms/adverse effects

Please log in/register to access.

Log in/Register

LinkedIn Facebook Twitter

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System.
All rights reserved. Terms of Use Privacy Statement

Back to top